A Phase 3 interventional study of Nifedipine and Placebo of Nifedipine in Preterm Premature Rupture of Membrane, sponsored by Assistance Publique - Hôpitaux de Paris. Active, not recruiting at 1 site in France. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-23.
Sponsored by Assistance Publique - Hôpitaux de Paris · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The purpose of this study is to assess whether short-term (48 hr) tocolysis reduces perinatal morti-morbidity in cases of PPROM at 22 to 33 completed weeks' gestation.
Preterm premature rupture of membranes (PPROM) complicates 3% of pregnancies and accounts for one-third of preterm births. It is a leading cause of neonatal mortality and morbidity and increases the risk of maternal infectious morbidity. In cases of early PPROM (22 to 33 completed weeks' gestation), expectant management is recommended in the absence of labor, chorioamnionitis or fetal distress. Antenatal steroids and antibiotics administration are recommended by international guidelines. However, there is no recommendation regarding tocolysis administration in the setting of PPROM. In theory, reducing uterine contractility should delay delivery and reduce risks of prematurity and neonatal adverse consequences. Likewise, a prolongation of gestation may allow administering a corticosteroids complete course that is associated with a two-fold reduction of morbidity and mortality. However, tocolysis may prolong fetal exposure to inflammation and be associated with higher risk of materno-fetal infection, potentially associated with neonatal death or long-term sequelae, including cerebral palsy.
The purpose of this study is to assess whether short-term (48 hr) tocolysis reduces perinatal morti-morbidity in cases of PPROM at 22 to 33 completed weeks' gestation.
76 studies on the registry are indexed under Preterm Premature Rupture of the Membranes; 17 are open to participants now.
This study's enrollment of 857 is above the median of 91 across 50 interventional studies indexed under Preterm Premature Rupture of the Membranes.
Browse Preterm Premature Rupture of the Membranes studies →Assistance Publique - Hôpitaux de Paris is the lead sponsor of 3,598 studies on the registry; 1,038 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Maternal allergy or to Nifedipine or placebo drug components*:
placebo drug components: lactose monohydrate, colloidal silica, microcrystalline cellulose
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Nifedipine
Drug: Placebo of Nifedipine
Loading dose: Oral Nifedipine 20 mg prolonged-release at T0 and T0.5 (i.e. 30 min), total=2x20 mg Maintenance dose: Oral Nifedipine 20 mg prolonged-release at T3, then 1 pill every 8 hr for 48 hr (i.e. T11, T19, T27, T35 and T43, total=6x20 mg)
Oral Placebo of Nifedipine 20 mg, at T0, T0.5, T3, T11, T19, T27, T35 and T43
Perinatal morti-morbidity
Composite outcome including fetal death, neonatal death and/or neonatal severe morbidity (mechanical ventilation ≥ 48 hrs, severe bronchopulmonary dysplasia, severe intraventricular hemorrhage, cystic periventricular leucomalacia, neonatal early-onset sepsis, necrotizing enterocolitis, retinopathy of prematurity).
Time frame: Up to discharge from hospital, with a maximum of 24 weeks after birth.
Prolongation of gestation
Latency duration (defined as the duration from PPROM to delivery)
Time frame: Up to 20 weeks after PPROM (i.e. up to the maximum duration of a normal pregnancy)
Prolongation of gestation
Pregnancy prolongation beyond 48 hours after randomization
Time frame: Up to 20 weeks after PPROM (i.e. up to the maximum duration of a normal pregnancy)
Prolongation of gestation
Pregnancy prolongation beyond 1 week after randomization
Time frame: Up to 20 weeks after PPROM (i.e. up to the maximum duration of a normal pregnancy)
Prolongation of gestation
Gestational age at delivery
Time frame: Up to 20 weeks after PPROM (i.e. up to the maximum duration of a normal pregnancy)
Prolongation of gestation
Delivery after 37 weeks of gestation
Time frame: Up to 20 weeks after PPROM (i.e. up to the maximum duration of a normal pregnancy)
Maternal morbidity
Endometritis, based on clinical diagnosis associating fever (temperature ≥ 38.0°C) with uterine tenderness, purulent or foul-smelling lochia, and in the absence of any other cause.
Time frame: During the first 10 days postpartum
Maternal morbidity
Intra-uterine infection, defined as fever (maternal temperature ≥38 °C), with no alternative cause identified, associated with at least two of the following criteria: persistent fetal tachycardia \> 160 bpm, uterine pain or painful uterine contractions or spontaneous labor, purulent amniotic fluid.
Time frame: At delivery
Fetal mortality
Fetal death
Time frame: Up to delivery so up to 20 weeks after PPROM (i.e. up to the maximum duration of a normal pregnancy)
Neonatal mortality
Neonatal death
Time frame: From birth to discharge from hospital, with a maximum of 24 weeks after birth.
Neonatal severe morbidity
Mechanical ventilation ≥ 48 hrs
Time frame: From birth to discharge from hospital, with a maximum of 24 weeks after birth.
Neonatal severe morbidity
Severe bronchopulmonary dysplasia
Time frame: From birth to discharge from hospital, with a maximum of 24 weeks after birth.
Neonatal severe morbidity
Severe intraventricular hemorrhage
Time frame: From birth to discharge from hospital, with a maximum of 24 weeks after birth.
Neonatal severe morbidity
Cystic periventricular leucomalacia
Time frame: From birth to discharge from hospital, with a maximum of 24 weeks after birth.
Neonatal severe morbidity
Early-onset sepsis
Time frame: From birth to Day 3 after birth.
Neonatal severe morbidity
Necrotizing enterocolitis
Time frame: From birth to discharge from hospital, with a maximum of 24 weeks after birth.
Neonatal severe morbidity
Retinopathy of prematurity
Time frame: From birth to discharge from hospital, with a maximum of 24 weeks after birth.
Neonatal morbidity
Severe fetal acidemia
Time frame: At birth.
Neonatal morbidity
Respiratory distress syndrome
Time frame: From birth to discharge from hospital, with a maximum of 24 weeks after birth.
Neonatal morbidity
Mild or moderate bronchopulmonary dysplasia
Time frame: From birth to discharge from hospital, with a maximum of 24 weeks after birth.
Neonatal morbidity
Grades I-II intraventricular hemorrhage
Time frame: From birth to discharge from hospital, with a maximum of 24 weeks after birth.
Neonatal morbidity
Late-onset sepsis.
Time frame: From Day 3 after birth to discharge from hospital, with a maximum of 24 weeks after birth.
Vital status
Death between discharge and follow up at 2 years
Time frame: At 22-26 months of corrected age
Frequency of Gross motor impairment among children alive at 2 years of corrected age
Cerebral palsy
Time frame: At 22-26 months of corrected age
Frequency of Neurosensory impairment among children alive at 2 years of corrected age
Visual impairment
Time frame: At 22-26 months of corrected age
Frequency of Neurosensory impairment among children alive at 2 years of corrected age
Hearing impairment
Time frame: At 22-26 months of corrected age
Plan to share: Undecided
Started Oct 2019 (actual). Primary completion is estimated for Nov 2026, 85 months after the start.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Nifedipine
Preterm Premature Rupture of the Membranes →
Assistance Publique - Hôpitaux de Paris →